124276-71-7

Basic information

• Product Name: 1-(3-methylphenyl)cyclopropane-1-carbonitrile
• Synonyms: 1-(3-methylphenyl)cyclopropane-1-carbonitrile
• CAS NO: 124276-71-7
• Molecular Formula: C₁₁H₁₁N
• Molecular Weight: 157.21174
• Mol File: 124276-71-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-methylphenyl)cyclopropane-1-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-methylphenyl)cyclopropane-1-carbonitrile(124276-71-7)
• EPA Substance Registry System: 1-(3-methylphenyl)cyclopropane-1-carbonitrile(124276-71-7)

Safety Data

• Hazardous Substances Data: 124276-71-7(Hazardous Substances Data)

Usage

General Description

1-(3-methylphenyl)cyclopropane-1-carbonitrile is a chemical compound with the molecular formula C11H11N. It is a member of the cyclopropane family, containing a three-membered ring of carbon atoms. The compound also contains a nitrile group, which consists of a carbon atom triple-bonded to a nitrogen atom. 1-(3-methylphenyl)cyclopropane-1-carbonitrile is used in organic synthesis as a building block for the preparation of various pharmaceutical and agrochemical products. It is also used as a precursor in the production of other complex organic compounds. As with all chemical compounds, 1-(3-methylphenyl)cyclopropane-1-carbonitrile should be handled and used with care, following all necessary safety precautions and regulations.

Upstream product

• 2947-60-6 3-methylbenzyl cyanide 
• 107-04-0 1-Bromo-2-chloroethane 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 106-93-4 ethylene dibromide 

Downstream Products

• 886366-16-1 1-(3-methylphenyl)-1-cyclopropanecarboxylic acid 
• 886366-44-5 (1-(m-tolyl)cyclopropyl)methanol 

Relevant articles and documents

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.